Clinical Study on Safety and Efficacy of Anti-CLL1 /+CD33 CAR T Cells in the Treatment of Acute Myeloid Leukemia

Inclusion Criteria: 1. The patient or his/her legal guardian volunteers for the trial and signs an informed consent form; 2. Age range 1-18 years; 3. Acute myeloid leukemia (AML) with CLL1 and CD33 markers (including secondary patients) was diagnosed by pathology, histology and flow cytometry, or complete hematologic remission could not be achieved after 1 course of chemotherapy for hematologic relapse after drug withdrawal ; 4. The main organ functions of the patients were good: (1) liver function: ALT/AST \< 3 times the upper limit of normal (ULN) and bilirubin ≤34.2 μmol/l; (2) renal function: creatinine \< 220 μmol/l; (3) lung function: oxygen saturation ≥95% ; (4) cardiac function: left ventricular ejection fraction (LVEF)≥40% ; 5. The blood flow of peripheral superficial vein was unobstructed, which could meet the demands of intravenous drip and mononuclear cell collection; 6. ECOG score was 0-2. Exclusion Criteria: 1. The patients had uncontrollable infectious diseases within 4 weeks before the enrollment; 2. Active hepatitis B/C virus; 3. HIV infection, treponema syphilis positive patients; 4. Pathological diagnosis of primary tumors other than acute myeloid leukemia; 5. Suffering from serious autoimmune diseases or immunodeficiency diseases; 6. The patient is allergic to antibodies or cytokines and other macromolecular biological drugs; 7. Pregnant or lactating women; 8. Patients who were considered ineligible for study for other reasons.